Following confirmation of a Department of Justice probe into its business practices and a disappointing earnings release, UnitedHealth Group’s stock has declined by 20% over the past month, continuing a sharp downward slide since the beginning of the year.
Strategist | strategy-catalyst
UnitedHealth’s stock continues to tumble after disappointing earnings and DOJ probe

Related Topics:
Payer StrategyRelevant Roles:
Chief Strategy Officers